64
Views
5
CrossRef citations to date
0
Altmetric
Original

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Etoposide (CHOPE) for Advanced-Stage Hodgkin's Disease: CALGB 8856

, M.D., , Ph.D., , M.D., , Ph.D., , M.D., , M.D., , M.D., , III, M.D. & , M.D. show all
Pages 447-458 | Published online: 31 May 2001

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mehul Dalal, Jatin Gupta, Kim Price, Athanasios Zomas, Harry Miao & Ajibade Ashaye. (2020) Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review. Expert Review of Hematology 13:8, pages 907-922.
Read now

Articles from other publishers (4)

Carolyn Compton. (2006) The Cancer and Leukemia Group B Pathology Committee at 50. Clinical Cancer Research 12:11, pages 3617s-3621s.
Crossref
Carol S. Portlock, Gerard B. Donnelly, Jing Qin, David Straus, Joachim Yahalom, Andrew Zelenetz, Ariela Noy, Owen O'Connor, Steven Horwitz, Craig Moskowitz & Daniel A. Filippa. (2004) Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease*. British Journal of Haematology 125:6, pages 701-708.
Crossref
Armando Santoro, Luca Castagna & Massimo Magagnoli. 2003. 399 428 .
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:1, pages 43-50.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.